Business Context and Reporting Period
West Pharmaceutical Services, Inc. filed this unaudited Form 10-Q for the quarter and six months ended June 30, 2012. The company operates through Pharmaceutical Packaging Systems, which supplies packaging components for injectable drug delivery, and Pharmaceutical Delivery Systems, which develops safety, administration, contract-manufacturing and proprietary drug-delivery systems.
Key Financial Metrics
| Metric | Q2 2012 | Q2 2011 | Six Months 2012 | Six Months 2011 |
|---|---|---|---|---|
| Net sales | $324.8 million | $307.9 million | $641.1 million | $603.3 million |
| Gross profit | $98.7 million | $84.6 million | $199.8 million | $172.6 million |
| Gross margin | 30.4% | 27.5% | 31.2% | 28.6% |
| Operating profit | $35.6 million | $27.8 million | $77.3 million | $56.5 million |
| Net income | $15.6 million | $20.1 million | $44.8 million | $39.7 million |
| Diluted EPS | $0.45 | $0.57 | $1.27 | $1.13 |
| Operating cash flow | Not separately provided | Not separately provided | $66.0 million | $49.2 million |
- Q2 sales increased 5.5%; six-month sales increased 6.3%. Excluding currency effects, management reported increases of 11.3% and 10.2%, respectively.
- Packaging Systems sales increased 6.1% in Q2 and 7.6% year to date; Delivery Systems sales increased 3.3% and 1.8%, respectively.
- Packaging Systems operating profit was $50.5 million in Q2 versus $38.1 million; Delivery Systems operating profit was $5.5 million versus $2.4 million.
- Q2 operating margin was approximately 11.0%, compared with 9.0% in the prior-year quarter. Six-month operating margin was approximately 12.1%, compared with 9.4%.
- Q2 net margin was approximately 4.8%, compared with 6.5%; six-month net margin was approximately 7.0%, compared with 6.6%.
- Capital expenditures were $69.4 million in the first six months, compared with $37.8 million in the prior-year period, primarily for a new corporate office and research building and a compression-molding plant in China.
- Cash and cash equivalents were $107.0 million at June 30, 2012, supplemented by $25.5 million of short-term investments. Working capital was $196.8 million.
- Total debt was $385.5 million, including $89.1 million classified as current and $296.4 million of long-term debt. Net debt-to-total invested capital was 29.1%, compared with 28.2% at December 31, 2011.
Material Changes Versus the Prior Comparable Period
- Gross profit increased 16.7% in Q2 and 15.8% for the first six months, driven by favorable product mix, volume, pricing and production efficiencies. Higher raw-material, wage and benefit costs partially offset the gains.
- Operating profit increased 28.1% in Q2 and 36.8% year to date, despite unfavorable foreign-exchange effects and higher research and development and selling, general and administrative costs.
- Net income declined 22.4% in Q2 because of an $11.6 million pretax loss on extinguishment of debt. The loss resulted from repurchasing $158.4 million of convertible debentures, or 98.06% of the outstanding principal.
- Six-month net income rose 12.8% despite the debt-extinguishment loss.
- Foreign currency translation produced a $29.4 million other comprehensive loss in Q2 and a $17.2 million loss for the first six months, versus gains in the prior-year periods.
- Operating cash flow increased by $16.8 million year over year, but substantially higher capital spending resulted in $67.8 million of investing cash outflows.
- The company entered into a new $300.0 million revolving credit facility expiring in April 2017. At June 30, $204.9 million was outstanding, with $91.8 million of borrowing capacity available.
Guidance, Outlook, Risks and Unusual Items
- Management stated that current liquidity is sufficient for operating needs, product development, capital expansion, pension and postretirement obligations, dividends and potential debt repayment, acquisitions or other investments.
- Management expected approximately $1.2 million of additional restructuring charges during the remainder of 2012, primarily cash severance and completion costs related to the 2010 restructuring plan.
- A $3.4 million impairment charge was recorded in Q2 for a Delivery Systems product line after continuing delays and lower-than-expected demand reduced projected cash flows.
- On July 5, 2012, the company issued $168.0 million of senior unsecured notes with maturities from 2022 through 2027. The weighted-average coupon was 3.87%, and the estimated effective rate, including hedging and transaction costs, was 4.16%. Proceeds were used to reduce revolving-credit borrowings.
- On July 30, 2012, the company used its revolving facility to repay $50.0 million of Series A floating-rate notes that matured on July 28.
- Key risks include demand and customer inventory changes, competition and pricing pressure, regulatory approval and commercialization of customer products, dependence on suppliers and partners, raw-material and energy costs, production or supply-chain disruptions, foreign-exchange volatility, execution of restructuring and capital projects, and development and commercialization risks for SmartDose and other proprietary systems.
- The company was in compliance with its debt covenants at June 30, 2012. Management reported no material changes to previously disclosed legal proceedings or risk factors and no material off-balance-sheet financing arrangements beyond operating leases, ordinary-course purchase obligations and letters of credit.
Important Facts for Investors to Verify
- Confirm the post-quarter-end refinancing impact on revolving-credit borrowings, total debt, interest expense and liquidity.
- Assess whether Packaging Systems growth, pricing and favorable mix can offset currency movements and rising material and labor costs.
- Monitor the impaired Delivery Systems product line, SmartDose commercialization and the $2.5 million SmartDose contingent-consideration liability.
- Evaluate capital-project completion, final settlement timing and total spending for the new corporate facility and China plant.
- Track restructuring completion costs, pension funding requirements and compliance with leverage and interest-coverage covenants.
- Consider the effect of the large foreign-currency translation loss on equity and the company’s ongoing exposure to exchange rates, interest rates and petroleum-based raw materials.